Proteomic Analysis in Paediatric Diabetes Type 1 (PAPD)

Launched by ARISTOTLE UNIVERSITY OF THESSALONIKI · Feb 4, 2020

Keywords

ClinConnect Summary

**Clinical Trial Summary: Proteomic Analysis in Paediatric Diabetes Type 1 (PAPD)**

This clinical trial is studying a specific type of blood test called "proteomic analysis" in children with Type 1 diabetes (T1D) to understand its role in detecting early signs of diabetic peripheral neuropathy, which is nerve damage that can occur in people with diabetes. While diabetic neuropathy is more common in adults, it can sometimes affect children as well. The researchers want to see if certain proteins in the blood can help identify children at risk for this condition before symptoms appear. The study will involve tests to measure how well nerves are functioning, along with the blood tests.

To participate in this study, children aged 5 to 10 who have been diagnosed with Type 1 diabetes and are managing their blood sugar levels well (with a specific target for their blood test results) can join. Their parents or guardians will need to give permission for them to take part. Children who have other chronic health issues or poor blood sugar control are not eligible. If chosen for the study, participants can expect to have blood samples taken and undergo nerve function tests, all while being closely monitored by the researchers. This study aims to find new ways to spot nerve problems early, which could help in managing diabetes more effectively.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Children with confirmed DT1 under insulin substitution therapy
• • 2. Age 5-10 years
• • 3. Good glycemic control with HbA1c ≤ 7.0%
• • 4. Prepubertal patients
• • 5. Absence of other diseases
• • 6. Signed informed consent of the parents or guardians of patients
• Exclusion Criteria:
• • 1. Presence of organic cause for neuropathy
• • 2. Presence of other chronic disease
• • 3. Poor glycemic control
• • 3. Medication